PathologybioRxivPreprint
In vivo intra-uterine delivery of TAT-fused Cre recombinase and CRISPR/Cas9 editing unveil histopathology of Pten/p53-deficient endometrial cancers.
R. Navaridas, M. Vidal-Sabanes, A. Ruiz-Mitjana…·X. Dolcet
This study shows that simultaneous deletion of Pten and p53 in endometrial epithelial cells leads to epithelial to mesenchymal transition and the formation of uterine carcinosarcomas in vivo.
DOI 10.1101/2023.06.08.544224